Scientific Steering Committee:
The components of this program were developed and reviewed by a Steering Committee of experts from Thrombosis Canada. The committee consisted of the following medical practitioners:
| Kerstin de Wit, MBChB, MSC, MD, MRCP, FRCEM, FRCPC (Chair)Thrombosis and Emergency Medicine
Hamilton, ON |
Lana Castellucci, MD, MSc, FRCPCThrombosis and Internal Medicine
Ottawa, ON |
| Vinai Bhagirath, MD, MSc, FRCPCHematology
Hamilton, ON |
Indy Gosh, MD, CCFP (ED)Emergency Medicine
Toronto, ON |
Program Learning Objectives
After completing all elements of this program, participants will be better able to:
- Apply evidence-based methodology in deciding which patients with PE may be discharged home safely and treated as an outpatient;
- Describe appropriate anticoagulation (e.g., DOAC, warfarin, LMWH) for DVT or PE in various patient populations (renal disease, obesity, cancer);
- Discuss potential drug-drug interactions when considering the use of DOACs or warfarin to treat VTE.
Case-specific Learning Objectives
Uncomplicated PE; Indy Ghosh
By the end of this case, participants will be able to:
- Describe one potential diagnostic algorithm for hemodynamically stable patients suspected of pulmonary embolism (PE);
- Apply evidence-based methodology in deciding which patients with PE may be discharged home safely and treated as an outpatient.
PE and Drug-drug Interactions; Lana Castellucci
By the end of this case, participants will be able to:
- Describe drug-drug interactions for DOACs;
- Discuss drug-drug interactions for warfarin.
PE in Obese Patients; Vinai Bhagirath
By the end of this case, participants will be able to:
- Understand risk of VTE in very obese patients;
- Choose appropriate initial treatment for VTE in very obese patients;
- Identify and appropriately consider factors that may necessitate a change from usual practice when treating patients with significant obesity and VTE.
Incidental Cancer-associated PE; Kerstin de Wit
By the end of this case, participants will be able to:
- Describe a safe approach to treatment of cancer-associated thrombosis (CAT);
- Review the anticoagulation options for CAT;
- Discuss the treatment of incidentally identified CAT.
DVT and Severe Renal Disease; Lana Castellucci
By the end of this case, participants will be able to:
- Describe use of DOACs in renal disease;
- Describe use of warfarin in renal disease.
Management of Upper Extremity DTV; Indy Ghosh
By the end of this case, participants will be able to:
- Discuss when to suspect upper extremity (UE) deep vein thrombosis (DVT);
- Describe the difference between primary and secondary UEDVT;
- Determine if diagnostic algorithm and treatment for UEDVT are the same as lower extremity (LE) DVT.
Management of DVT in thrombocytopenia; Vinai Bhagirath
By the end of this case, participants will be able to:
- Describe the risk of VTE in patients with cancer;
- Determine appropriate initial treatment for cancer- and chemotherapy-associated VTE in the presence of thrombocytopenia;
- Identify factors that may complicate VTE treatment specific to cancer and chemotherapy.
Management of DVT in patient with gastric cancer; Kerstin de Wit
By the end of this case, participants will be able to:
- Discuss why patients with a GI tumour and DVT should be treated differently to other patients with cancer;
- Describe how patients with an in-situ GI tumour have a higher risk of bleeding from the tumour when anticoagulated;
- Explain why patients with an in-situ GI tumour and acute VTE should be treated with LMWH.
Click here to access program: COMING SOON
This program provided with support by an unrestricted education grant from the BMS-Pfizer Alliance